Biosimilar Antibodies

Anti-TNFSF2/TNFα Antibody (hMAK195) is a fully human monoclonal antibody targeting human Tumor Necrosis Factor alpha (TNFα / TNFSF2). This recombinant antibody is produced in CHO cells and features a human IgG1 heavy chain paired with a human kappa light chain. The predicted molecular weight of the intact antibody is approximately 145.06 kDa. hMAK195 is suitable for applications involving TNFα pathway modulation, including in vitro neutralization assays and preclinical research in inflammation, autoimmune disease, or cancer models.

Calpurbatug is a human IgG1 monoclonal antibody specifically designed to bind members of the bacterial DNABII protein family, key structural components involved in the stability of bacterial biofilms. This antibody is functionally equivalent to anti-human monoclonal TRL1068 and carries a γ1 heavy chain. By targeting DNABII proteins, Calpurbatug disrupts the biofilm matrix and facilitates enhanced antimicrobial susceptibility, making it a valuable tool in bacterial pathogenesis studies and anti-biofilm therapeutic research.

Anti-FLT3 Antibody (AGS62P) is a high-affinity monoclonal antibody directed against human Fms-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase frequently overexpressed or mutated in acute myelogenous leukemia (AML). AGS62P is specifically designed for use in antibody-drug conjugate (ADC) development and demonstrates selective binding to FLT3-expressing cells. Due to its targeted nature, AGS62P is an ideal candidate for research in FLT3-driven malignancies, including AML, and can be utilized in preclinical models to evaluate therapeutic efficacy, drug delivery, and receptor-specific cytotoxicity.

Depemokimab (GSK-3511294) is a long-acting, high-affinity human monoclonal antibody specifically targeting interleukin-5 (IL-5), a key cytokine involved in the proliferation, activation, and survival of eosinophils. Engineered for extended half-life and sustained biological activity, Depemokimab is designed to enable infrequent dosing while maintaining effective IL-5 pathway blockade. This antibody is a valuable tool for preclinical research in eosinophilic asthma and other IL-5–mediated inflammatory diseases. Its pharmacokinetic and immunomodulatory properties make it suitable for evaluating long-term IL-5 inhibition in both in vitro and in vivo models.

Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1.

Tovecimig is a G1-scFv-based monoclonal antibody that specifically targets both vascular endothelial growth factor A (VEGFA) and Delta-like ligand 4 (DLL4), two key regulators of angiogenesis. By simultaneously inhibiting VEGFA and DLL4 signaling, Tovecimig offers a dual anti-angiogenic mechanism that may support research into tumor vascularization, resistance to anti-VEGF therapies, and other angiogenesis-dependent pathologies.

Bamlanivimab is a fully human monoclonal antibody targeting the spike protein of SARS-CoV-2. It was the first anti-COVID-19 antibody to receive Emergency Use Authorization (EUA) from the U.S. FDA. Bamlanivimab binds to the receptor-binding domain (RBD) of the spike protein, neutralizing viral entry into host cells. It is a valuable tool for research on viral infection mechanisms, therapeutic neutralization, and emerging variant resistance.

Palivizumab (MEDI 493) is a humanized IgG1 monoclonal antibody that targets the F protein of respiratory syncytial virus (RSV), a major cause of severe respiratory infections in infants and immunocompromised individuals. Palivizumab inhibits RSV fusion and entry into host cells, making it a critical research reagent for studying RSV pathogenesis, prophylaxis, and antibody-based antiviral strategies.

This monoclonal antibody specifically targets bone marrow stromal antigen 2 (BST2), also known as CD317 or tetherin, a protein involved in antiviral defense and immune regulation. BST2 is upregulated in various cancers and viral infections, making this antibody a useful tool for investigating tumor immunology, viral budding mechanisms, and innate immune signaling.

Dalidnetug is a humanized monoclonal antibody designed to selectively bind growth differentiation factor 15 (GDF-15), a member of the TGF-β superfamily associated with stress response, cancer progression, and metabolic regulation. This antibody enables research into GDF-15-mediated signaling pathways and is suitable for use in preclinical studies of oncology, cardiovascular disorders, and inflammation.

Eltrekibart is a human IgG4κ monoclonal antibody that targets CXCL chemokines, key mediators involved in leukocyte trafficking and inflammatory responses. By modulating CXCL-related pathways, Eltrekibart serves as a useful tool for investigating chronic inflammation, immune cell migration, and chemokine-receptor signaling in disease models. Recommended isotype control: Human IgG4 (S228P) kappa isotype control.

Radretumab is a CHO-expressed humanized IgG1κ monoclonal antibody targeting the extradomain B (ED-B) of fibronectin, an isoform selectively expressed in tumor neovasculature. Radretumab is designed for tumor-targeted delivery and is widely used in cancer research to study angiogenesis, extracellular matrix remodeling, and antibody-directed therapeutic strategies. Recommended isotype control: Human IgG1 kappa isotype control.

Lipustobart is a humanized IgG4κ monoclonal antibody directed against PD-1 (programmed cell death protein 1 / CD279), a key immune checkpoint receptor involved in T cell regulation. By blocking PD-1 signaling, Lipustobart restores T cell activity and promotes antitumor immune responses. This antibody is suitable for research in cancer immunotherapy, immune checkpoint blockade, and T cell exhaustion.

Girentuximab (G250) is a chimeric IgG1 monoclonal antibody that selectively binds carbonic anhydrase IX (CAIX), a transmembrane glycoprotein highly expressed in clear cell renal cell carcinoma (ccRCC) and hypoxic tumor environments. It is widely used in tumor imaging, targeted therapy development, and CAIX-related cancer biology studies.

Teclistamab is a human bispecific antibody that simultaneously targets B cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells. By engaging both cell types, Teclistamab induces T cell activation and redirects cytotoxic responses toward BCMA-expressing cells. This bispecific format is widely used in preclinical models of multiple myeloma to study T cell–mediated antitumor activity and immune cell redirection strategies.

Pacanalotamab is a bispecific T-cell engager (BiTE®) antibody construct targeting B cell maturation antigen (BCMA) and CD3ε. By bridging T cells and BCMA-expressing multiple myeloma cells, Pacanalotamab promotes potent T cell–mediated cytotoxicity. It is a valuable tool for preclinical evaluation of immune cell redirection and targeted therapies in hematologic malignancies.

Etigilimab is a humanized IgG1 monoclonal antibody that blocks the interaction between TIGIT and its ligand CD155 (PVR), a key pathway in immune checkpoint regulation. By inhibiting TIGIT signaling, Etigilimab enhances T cell–mediated immune responses and is widely used in tumor immunology research and checkpoint blockade studies.

Ralpancizumab is a selective monoclonal antibody inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of LDL receptor degradation. While primarily studied in cardiovascular research, Ralpancizumab is also being investigated for its potential role in hemorrhagic stroke models, offering insights into lipid metabolism and vascular injury.

Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2 (HER2), a member of the epidermal growth factor receptor family implicated in the progression of various cancers. Timigutuzumab is suitable for preclinical research on HER2-driven oncogenesis, targeted therapy development, and antibody-mediated cytotoxicity.

Anti-c-RET is a monoclonal antibody targeting the receptor tyrosine kinase RET (c-RET), which is expressed in neural crest-derived tumors such as neuroblastoma and in dopaminergic neurons of the substantia nigra. This antibody is useful for studying RET signaling in the context of oncogenesis and neurodegenerative disorders, including Parkinson’s disease.

Abagovomab is a murine anti-idiotypic monoclonal antibody that mimics the tumor-associated antigen CA-125. Generated from mouse hybridoma technology, it is capable of eliciting both humoral and cellular immune responses. Abagovomab is used in ovarian cancer research, particularly in studies of immunotherapy and tumor antigen mimicry.

Anti-FGF19 (clone 1A6) is a humanized monoclonal antibody that selectively binds fibroblast growth factor 19 (FGF19), a key mitogen implicated in hepatocellular carcinoma (HCC). This antibody demonstrates antitumor activity by disrupting FGF19-mediated signaling, and is suitable for research in liver cancer models and FGFR4 pathway modulation.

Ordesekimab is a fully human IgG1κ monoclonal antibody that targets interleukin-15 (IL-15). It blocks the interaction of IL-15 with the IL-2Rβ and common γ chain components of the IL-15 receptor complex, without affecting binding to IL-15Rα. Ordesekimab is a valuable tool for studying IL-15–driven immune responses and is under investigation for use in nonresponsive celiac disease (NRCD).

MEDI-578 is a CHO-expressed human monoclonal antibody that targets nerve growth factor (NGF), including its biologically active β-subunit (β-NGF). Featuring a human IgG2a heavy chain and lambda light chain, MEDI-578 is suitable for preclinical research into pain signaling, neurotrophin biology, and inflammation-related disorders. Recommended isotype control: Human IgG4 kappa isotype control.

Nipocalimab is a fully human, recombinant IgG1 monoclonal antibody engineered to lack Fc glycosylation. It binds with high affinity to the neonatal Fc receptor (FcRn), blocking the recycling and transcytosis of IgG. Nipocalimab is used in research on IgG-mediated autoimmune diseases, including hemolytic disease of the fetus and newborn (HDFN) and myasthenia gravis.

Margetuximab is a chimeric anti-HER2 IgG1 monoclonal antibody engineered with an optimized Fc domain to enhance antibody-dependent cellular cytotoxicity (ADCC). With an EC₅₀ of 39.33 ng/mL, Margetuximab is used in the study of HER2-positive metastatic breast cancer and immune effector cell engagement.

Anti-CXCL9 is a humanized IgG1κ monoclonal antibody expressed in CHO cells, specifically targeting the chemokine CXCL9. This antibody is used in inflammation and tumor immunology research, particularly in contexts involving chemokine-mediated immune cell recruitment. Recommended isotype control: Human IgG1 kappa isotype control.

Nadecnemab is an IgG4κ monoclonal antibody that targets GDNF family receptor alpha 3 (GFRA3), a receptor involved in neurotrophic signaling. Nadecnemab is suitable for research into chronic pain and osteoarthritis of the knee, particularly in models examining the GDNF–RET signaling axis.

Etaracizumab is a human IgG1 monoclonal antibody that targets the integrin αvβ3, which plays a critical role in angiogenesis, tumor invasion, and metastasis. By inhibiting αvβ3-mediated cell adhesion and migration, Etaracizumab is used in research on cancer biology, anti-angiogenic therapies, and metastatic melanoma.

Vudalimab is a fully human bispecific monoclonal antibody targeting both PD-1 and CTLA-4, two key immune checkpoint receptors. By simultaneously blocking these pathways, Vudalimab enhances T-cell activation in the tumor microenvironment and is widely used in research on immune checkpoint blockade, tumor immunology, and combination immunotherapy strategies.

Larcaviximab (c4G7-N) is a chimeric IgG1κ monoclonal antibody that targets the glycoprotein of the Ebola virus. It is designed to neutralize viral entry and fusion, and serves as a valuable research tool for investigating Ebola virus pathogenesis, antibody-based viral neutralization, and therapeutic antibody development against filoviruses.

Pagibaximab is a chimeric IgG1 monoclonal antibody directed against lipoteichoic acid (LTA), a surface component of Staphylococcus aureus and Staphylococcus epidermidis. It is primarily used in research related to neonatal sepsis and staphylococcal infections, with applications in pathogen-specific immune response and anti-bacterial antibody therapy.

Teplizumab is a humanized Fc receptor–nonbinding anti-CD3 monoclonal antibody that modulates T cell function and reduces β-cell destruction. It is commonly used in preclinical and clinical research focused on autoimmune diabetes, particularly in delaying or preventing the onset of type 1 diabetes.

Azerutamig is a bispecific monoclonal antibody that simultaneously targets KLRK1 (NKG2D) and ERBB2 (HER2). Based on a scFv-Fc architecture, this antibody facilitates immune cell redirection and cytotoxicity toward HER2-positive tumor cells expressing NKG2D ligands. Azerutamig is suitable for research in cancer immunotherapy and bispecific antibody engineering..

Balugrastim is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) generated through genetic fusion with human serum albumin. Designed to prolong serum half-life, Balugrastim promotes neutrophil production and is used in preclinical models of chemotherapy-induced neutropenia and breast cancer–associated myelosuppression.

Litifilimab is a humanized IgG1κ monoclonal antibody targeting CLEC4C (blood dendritic cell antigen 2, BDCA2), a receptor selectively expressed on plasmacytoid dendritic cells. Litifilimab is used in the study of autoimmune skin disorders, including cutaneous lupus erythematosus (CLE), for its role in modulating type I interferon production.

Tizetatug is a bispecific IgG1κ monoclonal antibody targeting TACSTD2 (TROP2), a transmembrane glycoprotein commonly overexpressed in epithelial cancers. Tizetatug is designed for dual antigen engagement and is suited for use in studies of TROP2-directed cancer therapy and antibody-based tumor targeting. Recommended isotype control: Human IgG1 kappa isotype control.

Finotonlimab (SCT-I10A) is a recombinant humanized IgG monoclonal antibody targeting PD-1, a critical immune checkpoint molecule. By blocking PD-1 signaling, Finotonlimab restores T cell activity and is applicable in research on solid tumors, lymphomas, and immune checkpoint inhibitor development.

Tislelizumab is a humanized monoclonal antibody that binds to the PD-1 receptor, effectively blocking its interaction with the ligands PD-L1 and PD-L2. By reactivating exhausted T cells, Tislelizumab enhances antitumor immunity. It is widely used in immuno-oncology research, including studies on Hodgkin’s lymphoma, urothelial carcinoma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma.

Pembrolizumab (MK-3475) is a humanized IgG4 monoclonal antibody that targets PD-1, a key immune checkpoint receptor. It inhibits the PD-1/PD-L1 pathway, restoring T cell activity and promoting tumor cell clearance. Pembrolizumab is a standard research tool for cancer immunotherapy and immune checkpoint inhibitor studies across a wide range of solid tumors.

Lunsekimig is a multispecific monoclonal antibody comprising five tandemly linked variable heavy chain domains that target thymic stromal lymphopoietin (TSLP), interleukin-13 (IL-13), and albumin (ALB). This engineered format offers enhanced functionality and half-life extension and is used in research on allergic inflammation and respiratory diseases such as asthma.

Manfidokimab (AK120) is a human IgG4 monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), a shared subunit of the IL-4 and IL-13 receptors. By inhibiting IL-4Rα signaling, Manfidokimab modulates type 2 inflammation and is used in research on asthma, atopic dermatitis, and other allergic conditions.

Bosakitug is a humanized IgG1κ monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine involved in allergic and epithelial-driven inflammation. This antibody is suitable for preclinical models of asthma, chronic rhinosinusitis, and other type 2 immune disorders. Recommended isotype control: Human IgG1 kappa isotype control.

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of LDL receptor degradation. By reducing circulating LDL cholesterol, Bococizumab is used in preclinical studies of hypercholesterolemia and cardiovascular risk reduction.

Regdanvimab (CT-P59) is a fully human monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, preventing viral entry by blocking ACE2 interaction. It is widely used in COVID-19 research, including viral neutralization, variant efficacy assessment, and therapeutic antibody development.

Betinukibart is a human IgG1κ monoclonal antibody targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. This antibody is used in preclinical research on IL-17–mediated pathways in conditions such as psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Recommended isotype control: Human IgG1 kappa isotype control.